CG
SLRN

Cutler Group’s ACELYRIN SLRN Stock Holding History

Cutler Group’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,700
Closed -$11K – 4283
2023
Q3 		$11K Buy
+3,700
New +$78.6K ﹤0.01% 2437

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Cutler Group's SLRN Position: Q1 2024 in Review

Cutler Group reduced its ACELYRIN (SLRN) stake by 72% in Q1 2024, selling an estimated $44.9K and leaving 2,294 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Cutler Group first reported a position in SLRN in Q3 2023 and has held it in 3 quarters since. The position peaked at $104K in Q3 2023. 109 funds tracked by Wall St. Rank hold SLRN as of Q1 2024.

  • Cutler Group held 2,294 shares of ACELYRIN worth $15K as of Q1 2024.
  • Cutler Group sold 5,906 ACELYRIN shares in Q1 2024, an estimated $44.9K.
  • ACELYRIN made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1123 holding.
  • Cutler Group first reported a position in ACELYRIN in Q3 2023 and has held it in 3 quarters since.
  • Cutler Group's ACELYRIN position peaked at $104K in Q3 2023.
  • 109 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.